Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Siedlce
Clinical trial register · Poland

Clinical Trials in Siedlce, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2716 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:18 UTC
2716
Studies in scope
all four open statuses
1383
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Warsaw 1322 Krakow 882 Poznan 697 Gdansk 665 Lodz 621

Trials with a site in Siedlce

81 of 2716 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Not yet open
Vortosiran for VTE Prevention
NCT07850453Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
Ribocure Pharmaceuticals AB
Phase 2
150
Gdynia, Grodzisk Mazowiecki, Krakow, Otwock, Poznan, Siedlce, Skorzewo, Szczecin
2026-10
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Skórzewo, Krakow, Wroclaw, Otwock, Siedlce, Warsaw, Opole, Przemyśl
2026-09-11
Recruiting
AstraZeneca
Phase 3
915
Gdansk, Koszalin, Poznan, Siedlce, Skórzewo, Wroclaw
2026-07-16
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość
2026-05-04
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Gdansk, Krakow, Poznan, Siedlce, Szczecin
2026-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Skórzewo, Krakow, Siedlce, Warsaw, Gliwice
2026-04-09
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Bialystok, Bydgoszcz, Dębica, Lublin, Pabianice, Poznan, Ruda Śląska, Siedlce
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Poznan, Siedlce, Bialystok, Szczecin
2026-02-16
Active, closed
Kailera
Phase 3
1,270
Bydgoszcz, Torun, Krakow, Lublin, Siedlce, Warsaw, Bialystok, Gdynia
2026-01-12
Active, closed
Kailera
Phase 3
2,530
Poznan, Torun, Krakow, Siedlce, Warsaw, Skierniewice, Zamość
2025-12-18
Recruiting
Incyte Corporation
Phase 3
466
Bialystok, Gdansk, Kielce, Siedlce, Szczecin
2025-12-09
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Lodz, Poznan, Przemyśl, Siedlce, Warsaw
2025-11-30
Recruiting
Genmab
Phase 3
660
Lublin, Siedlce, Bialystok, Szczecin, Kielce, Lodz
2025-11-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Skórzewo, Bydgoszcz, Krakow, Siedlce, Warsaw, Przemyśl, Koszalin
2025-11-26
Recruiting
Eli Lilly and Company
Phase 3
1,630
Bialystok, Gdansk, Krakow, Poznan, Siedlce
2025-10-22
Active, closed
Gesynta Pharma AB
Phase 2
213
Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Siedlce, Skorzewo, Szczecin
2025-10-15
Recruiting
Daiichi Sankyo
Phase 3
710
Bialystok, Gdynia, Poznan, Siedlce
2025-09-30
Recruiting
GlaxoSmithKline
Phase 3
420
Gliwice, Kielce, Lodz, Olsztyn, Otwock, Poznan, Przemyśl, Siedlce
2025-08-11
Recruiting
AstraZeneca
Phase 3
800
Lodz, Siedlce
2025-08-01
Recruiting
Celcuity Inc
Phase 3
1,180
Siedlce, Bydgoszcz, Konin, Krakow, Lodz, Opole, Szczecin, Warsaw
2025-07-24
Active, closed
Immunovant Sciences GmbH
Phase 2
180
Bydgoszcz, Krakow, Lodz, Lublin, Poznan, Siedlce, Warsaw, Wołomin
2025-06-30
Recruiting
BioNTech SE
Phase 3
480
Bialystok, Poznan, Siedlce
2025-06-10
Recruiting
Eikon Therapeutics
Phase 2/3
740
Gdansk, Konin, Siedlce, Gliwice, Warsaw
2025-05-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Katowice
2025-05-13
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
Poznan, Wroclaw, Siedlce, Warsaw, Wołomin, Bydgoszcz, Katowice, Lublin
2025-04-23
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
Corcept Therapeutics
Phase 2
270
Gdynia, Siedlce
2025-04-11
Recruiting
Gilead Sciences
Phase 3
695
Lodz, Poznan, Rzeszów, Siedlce, Stupsk, Warsaw
2025-04-04
Recruiting
Daiichi Sankyo
Phase 3
510
Lublin, Siedlce, Warsaw
2025-03-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Bialystok, Gdynia
2025-03-16
Active, closed
Genmab
Phase 3
584
Krakow, Bialystok, Gdansk, Lodz, Poznan, Siedlce, Szczecin
2025-02-07
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
Phase 2/3
650
Gdansk, Gliwice, Katowice, Konin, Krakow, Siedlce, Warsaw
2025-01-28
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Bydgoszcz, Dębica, Krakow, Lublin, Olsztyn, Poznan, Siedlce, Warsaw
2024-12-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Siedlce, Warsaw
2024-11-21
Active, closed
Ipsen
Phase 2
670
Częstochowa, Katowice, Krakow, Lodz, Oświęcim, Pomorskie, Puławy, Siedlce
2024-10-10
Recruiting
Daiichi Sankyo
Phase 1/2
680
Krakow, Lodz, Rzeszów, Siedlce, Skorzewo
2024-04-10
Recruiting
GlaxoSmithKline
Phase 3
864
Bielsko-Biala, Gliwice, Katowice, Olsztyn, Przemyśl, Siedlce, Warsaw
2024-03-21
Recruiting
Verastem, Inc.
Phase 3
270
Bialystok, Gdansk, Siedlce
2024-03-18
Recruiting
Daiichi Sankyo
Phase 2/3
860
Bialystok, Gdansk, Poznan, Siedlce
2024-02-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Bydgoszcz, Grudziądz, Torun, Siedlce, Koszalin, Szczecin, Kielce
2023-12-31
Recruiting
AstraZeneca
Phase 3
1,145
Bialystok, Bielsko-Biala, Bydgoszcz, Gliwice, Olsztyn, Piotrkow Trybunalski, Siedlce, Tomaszów Mazowiecki
2023-12-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Poznan, Siedlce, Warsaw, Bialystok
2023-12-06
Active, closed
GlaxoSmithKline
Phase 2
316
Bielsko-Biala, Katowice, Krakow, Przemyśl, Siedlce, Warsaw
2023-11-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Poznan, Bydgoszcz, Siedlce, Warsaw, Bialystok, Gdansk, Gliwice, Szczecin
2023-07-19
Active, closed
AbbVie
Phase 3
520
Poznan, Krakow, Siedlce, Gdynia
2023-03-15
Active, closed
Celcuity Inc
Phase 3
701
Bydgoszcz, Konin, Krakow, Lodz, Opole, Siedlce, Szczecin, Warsaw
2022-12-08
Active, closed
GlaxoSmithKline
Phase 2
351
Lublin, Prabuty, Siedlce
2022-10-14
Active, closed
Eli Lilly and Company
Phase 3
8,000
Gdynia, Koszalin, Lodz, Opole, Oświęcim, Siedlce, Torun, Warsaw
2022-10-04
Active, closed
Exelixis
Phase 3
901
Bydgoszcz, Opole, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-09-07
Active, closed
Gilead Sciences
Phase 3
623
Gdansk, Gliwice, Opole, Siedlce, Warsaw
2022-07-20
Active, closed
Corcept Therapeutics
Phase 3
381
Gdynia, Poznan, Siedlce
2022-06-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Konin, Poznan, Siedlce, Warsaw, Przemyśl, Prabuty, Bystra
2022-03-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Konin, Poznan, Bydgoszcz, Torun, Tarnów, Siedlce, Warsaw, Przemyśl
2022-03-15
Active, closed
AstraZeneca
Phase 3
1,051
Bydgoszcz, Gdansk, Koszalin, Poznan, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Poznan, Lublin, Siedlce, Warsaw, Bialystok, Gliwice, Kielce
2022-02-03
Active, closed
Gilead Sciences
Phase 3
603
Konin, Lodz, Rzeszáw, Siedlce
2021-11-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Bydgoszcz, Krakow, Siedlce, Warsaw, Wieliszew, Przemyśl, Bialystok, Gliwice
2021-06-18
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Siedlce, Skorzewo, Warsaw, Wroclaw
2020-12-07
Active, closed
Bayer
Phase 3
774
Lublin, Otwock, Siedlce, Warsaw, Lodz
2020-10-20
Active, closed
AstraZeneca
Phase 3
640
Katowice, Krakow, Lodz, Siedlce, Warsaw
2020-10-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Siedlce, Warsaw, Gdynia, Olsztyn
2020-07-06
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Bydgoszcz, Gdansk, Gdynia, Lodz, Siedlce, Szczecin, Warsaw, Wroclaw
2019-01-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Poznan, Torun, Krakow, Tarnów, Wroclaw, Siedlce, Warsaw, Przemyśl
2018-12-24
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Bialystok, Bydgoszcz, Krakow, Kutno, Lodz, Lublin, Siedlce, Sochaczew
2015-11-27
Rows per page Showing 1–81 of 81
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 November 2026. https://priyalifescience.com/clinical-trials-poland/city/siedlce

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,716 studies in total at the last sync on 15 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 81 of those studies with a site in Siedlce.

How many clinical trials are recruiting in Siedlce?

38 of the 81 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 42 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Siedlce), 81 studies
PhaseStudiesRecruitingShare
Phase 3652980.2%
Phase 212514.8%
Phase 2/3333.7%
Phase 1/2111.2%

Most active sponsors

Lead sponsors with the most studies (Siedlce)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC229
AstraZeneca64
Daiichi Sankyo55
Gilead Sciences51
GlaxoSmithKline52
Eli Lilly and Company43
Janssen Research & Development, LLC40
AbbVie21
Celcuity Inc21
Corcept Therapeutics21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.